IRSF awards $1.5 million for novel basic and translational research programs

January 14, 2013

Cincinnati, (OH) - The International Rett Syndrome Foundation (IRSF) broadened and intensified its efforts to produce treatments for Rett syndrome and related disorders, announcing today that it is awarding another $1.5M to support 18 new grants at leading global research institutions. In 2012, IRSF invested nearly $4M in high-quality, peer-reviewed research grants that give promise to advancing treatment strategies of Rett syndrome and other MECP2 disorders. The grants awarded today are designed to study a variety of diverse topics from basic discovery science and disease pathology to testing compounds and developing outcome measures for Rett syndrome. IRSF is the world's largest private source of funding for biomedical and clinical Rett syndrome research. Since 1998, IRSF has funded $30M in innovative research grants which have produced critical breakthroughs to advance the understanding of this neurological condition.

IRSF funds pioneering studies in Basic Research that aim to discover new avenues that may be amendable to novel therapies. IRSF also seeks to bridge the critical translational funding gap by investing in Translational Research that includes both pre-clinical and clinical studies. In an effort to recruit future Rett researchers, IRSF creates fellowships to outstanding post-doctoral research scientists and clinical scientists.

The awarded basic research projects cover discovery topics from epigenetics and gene regulation to understanding pathways and other neuronal cell types in Rett syndrome. Together, these studies will allow for identification of new therapeutic targets in Rett syndrome. The second round of translational grants is focused on gene therapy approaches, development and testing of potential therapeutic compounds, and development of outcome measures in humans that will be used in future clinical studies.

"This year's call for proposals produced our largest number of outstanding quality grant applications to IRSF in the history of the organization," commented Steven Kaminsky, PhD, the Chief Science Officer of IRSF. "The astounding response from the science community to our call bodes well for Rett syndrome research and illustrates the growing number of researchers exploring the biology surrounding Rett syndrome and possible treatments that will modify its course." Dr. Kaminsky added, "As more and more fundamental discoveries are made and translated into pre-clinical and clinical trials each year, we get closer to our goal of modifying the biology surrounding Rett syndrome and improving the lives of our Rett patients and their families. With the help of a superb group of reviewers, we have built a plan that funds the best of the best. We look forward to working with these investigators as we continue to push our mission to reverse Rett syndrome."

New Translational Research Awards
New Basic Research Awards-Regular Research Grants

New Mentored Training Fellowships

"The possibility of new treatments for Rett syndrome increases as our research program broadens and intensifies," said Dr. Kaminsky. "I would like to thank our Board and our donors for their demonstrated commitment to advancing the best science in the community."
-end-
About Rett Syndrome

Rett syndrome (RTT), a neurological disorder, occurs almost exclusively in females. RTT results in severe movement and communication problems following apparently normal development for the first six to 18 months of life. Characteristic features of the disease include loss of speech and purposeful hand use, repetitive hand movements, abnormal walking, abnormal breathing, slowing in the rate of head growth and increased risk of seizures. Current treatment for girls with RTT includes physical and occupational therapy, speech therapy, and medication for seizures. There is no known cure for RTT. In 2007, researchers heralded a major breakthrough by reversing RTT symptoms in mouse models. RTT is considered a "Rosetta Stone" that is helping scientists understand multiple developmental neurological disorders, and shares genetic links with other conditions such as autism and schizophrenia.

About the International Rett Syndrome Foundation.


IRSF is the world's leading private funder of basic, translational and clinical Rett syndrome research, funding $30M in high-quality, peer-reviewed research grants and programs to date. Annually, IRSF hosts the world's largest gathering of global Rett researchers and clinicians to establish research direction and priorities while exchanging ideas and the most recent information. IRSF is the most comprehensive non-profit organization dedicated to providing thorough and accurate information about Rett syndrome, offering informational and emotional family support, and stimulating research aimed at accelerating treatments and a cure for Rett syndrome and related disorders. IRSF has earned Charity Navigator's most prestigious 4 star rating. To learn more about IRSF and Rett syndrome, visit www.rettsyndrome.org or call IRSF at 1-800-818-RETT (7388).

International Rett Syndrome Foundation

Related Clinical Trials Articles from Brightsurf:

Nearly 1 in 5 cancer patients less likely to enroll in clinical trials during pandemic
A significant portion of cancer patients may be less likely to enroll in a clinical trial due to the ongoing coronavirus pandemic.

COVID-19 clinical trials lack diversity
Despite disproportionately higher rates of COVID-19 infection, hospitalization and death among people of color, minority groups are significantly underrepresented in COVID-19 clinical trials.

Why we should trust registered clinical trials
In a time when we have to rely on clinical trials for COVID-19 drugs and vaccines, a new study brings good news about the credibility of registered clinical trials.

Inclusion of children in clinical trials of treatments for COVID-19
This Viewpoint discusses the exclusion of children from coronavirus disease 2019 (COVID-19) clinical trials and why that could harm treatment options for children.

Review evaluates how AI could boost the success of clinical trials
In a review publishing July 17, 2019 in the journal Trends in Pharmacological Sciences, researchers examined how artificial intelligence (AI) could affect drug development in the coming decade.

Kidney patients are neglected in clinical trials
The exclusion of patients with kidney diseases from clinical trials remains an unsolved problem that hinders optimal care of these patients.

Clinical trials beginning for possible preeclampsia treatment
For over 20 years, a team of researchers at Lund University has worked on developing a drug against preeclampsia -- a serious disorder which annually affects around 9 million pregnant women worldwide and is one of the main causes of death in both mothers and unborn babies.

Underenrollment in clinical trials: Patients not the problem
The authors of the study published this month in the Journal of Clinical Oncology investigated why many cancer clinical trials fail to enroll enough patients.

When designing clinical trials for huntington's disease, first ask the experts
Progress in understanding the genetic mutation responsible for Huntington's disease (HD) and at least some molecular underpinnings of the disease has resulted in a new era of clinical testing of potential treatments.

New ALS therapy in clinical trials
New research led by Washington University School of Medicine in St.

Read More: Clinical Trials News and Clinical Trials Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.